More than 300 drugs are recognised as causing respiratory disease and, in particular, ILDs. Therefore, there is a need to register and communicate such drug effects across Europe and to establish guidelines for early detection, treatment and prevention of drug-induced ILDs.

A more intensive approach by national health authorities is required, in order to improve diagnosis and find safe and effective treatments for ILDs.

Large-scale epidemiological studies on ILDs are needed to improve knowledge of individual genetic susceptibility for the different ILDs and the pathogenetic effects of external agents.

More comprehensive information is required on possible genetic influences on the development of ILDs.